Adjunctive favipiravir for severe COVID-19: a retrospective observational study of the first 41 patients in Thailand

[1]Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential counter-measure against neglected and emerging RNA viruses. Antiviral Res. 2018; 153:85–94.DelangLAbdelnabiRNeytsJFavipiravir as a potential counter-measure against neglected and emerging RNA virusesAntiviral Res2018153859410.1016/j.antiviral.2018.03.003Search in Google Scholar

[2]Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14:58–60.DongLHuSGaoJDiscovering drugs to treat coronavirus disease 2019 (COVID-19)Drug Discov Ther202014586010.5582/ddt.2020.01012Search in Google Scholar

[3]Du YX, Chen XP. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther. 2020; 108:242–7. doi: 10.1002/cpt.1844.DuYXChenXPFavipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infectionClin Pharmacol Ther2020108242710.1002/cpt.1844Open DOISearch in Google Scholar

[4]Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with Favipiravir for COVID-19: an open-label control study. Engineering (in print). 2020. doi: 10.1016/j.eng.2020.03.007. Online ahead of print.CaiQYangMLiuDChenJShuDXiaJExperimental treatment with Favipiravir for COVID-19: an open-label control studyEngineering (in print)202010.1016/j.eng.2020.03.007Online ahead of print.Open DOISearch in Google Scholar

[5]Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv 2020.03.17.20037432. doi: 10.1101/2020.03.17.20037432ChenCZhangYHuangJYinPChengZWuJFavipiravir versus arbidol for COVID-19: a randomized clinical trialmedRxiv2020.03.17.2003743210.1101/2020.03.17.20037432Open DOISearch in Google Scholar

[6]Pongpirul W, Mott J, Woodring J, Uyeki T, MacArthur J, Vachiraphan A, et al. Clinical characteristics of initial hospitalized COVID-19 patients in Thailand. Emerg Infect Dis. 2020; 26:1580–5.PongpirulWMottJWoodringJUyekiTMacArthurJVachiraphanAClinical characteristics of initial hospitalized COVID-19 patients in ThailandEmerg Infect Dis2020261580510.3201/eid2607.200598Search in Google Scholar

[7]Pongpirul WA, Pongpirul K, Ratnarathon AC, Prasithsirikul W. Journey of a Thai taxi driver and novel coronavirus. N Engl J Med. 2020; 382:1067–8.PongpirulWAPongpirulKRatnarathonACPrasithsirikulWJourney of a Thai taxi driver and novel coronavirusN Engl J Med20203821067810.1056/NEJMc2001621Search in Google Scholar

[8]von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007; 4:e296.vonElm EAltmanDGEggerMPocockSJGotzschePCVandenbrouckeJPThe strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studiesPLoS Med20074e29610.1371/journal.pmed.0040296Search in Google Scholar